Navigation Links
Scripps Research scientists show how memory B cells stay 'in class' to fight different infections
Date:5/7/2012

viruses and bacteria. IgA-class B cells are predominantly found on mucosal surfaces such as in the throat and intestines. IgE-class cells and their antibodies protect against intestinal worms and other parasites. Some B cells stay in the default IgM class. The class of a B cell is marked by the type of "stem" it has on its Y-shaped antibodies; this stem, or effector, can mobilize other elements of the immune system, such as inflammatory chemicals, when the antibody binds to an invader.

It had been long assumed that the switching of a B cell to a particular class is the result of a one-time signaling event. "The idea was that the signals that produce this switch don't persist in B memory cells, for example," said Nathaniel Wang, a graduate student in the Scripps Research Kellogg School of Science and Technology working in the McHeyzer-Williams laboratory who was first author of the new study.

Testing Assumptions

In the study, Wang, McHeyzer-Williams, and their colleagues tried to determine whether that assumption is true. They knew, for example, that when T cells cause nave B cells to switch to the IgG2a class, a potent antiviral class, they do so by inducing the production in B cells of a particular protein called T-bet. To clarify T-bet's role, the researchers engineered transgenic mice whose B cells lack the protein.

Without T-bet, they found, the mouse B cells could not be switched to the IgG2a class, even when presented with all the normal stimuli, and even though other IgG classes could be produced normallyor even in higher amounts. Even more surprisingly, in existing IgG2a memory B cells, the abrupt knockdown of T-bet levels caused the cells to lose their ability to respond to a new infection. In fact, most of the T-bet-deprived memory B cells became undetectable within a few days.

"T-bet turns out to be the central molecule that enforces the IgG2a class in B cells, and if its production stops in IgG2a mem
'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Scripps Health Begins Pioneering Study of Human Tumor Sequencing in Cancer Patients
2. Top Scientists Explore the Origin of Life in Annual Lasker Lecture at Scripps Research Institute Florida Campus
3. Scripps Blood & Marrow Transplant Program Celebrates 30th Anniversary of Providing Life-Saving Care
4. Scripps Memorial Hospital La Jolla First in San Diego to Achieve Magnet Nursing Re-designation
5. Scripps Announces Plans for Region's First Proton Therapy Center; $185 Million Facility to Offer Advanced Care to Cancer Patients
6. Scripps Research scientists share $2 million in Florida state research grants
7. Scripps Center for Executive Health Now Offers Genetic Testing
8. Scripps Research scientists uncover previously unknown natural mechanism that controls cocaine use
9. NIH awards Scripps Florida scientists $2.3 Million to develop drug addiction treatments
10. Scripps Research scientists solve long-standing mystery of protein quality control mechanism
11. Scripps and Trius team up to develop new antibiotics with US Department of Defense grant
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Research scientists show how memory B cells stay 'in class' to fight different infections
(Date:12/24/2014)... 2014 New studies reveal that women under ... related depression (March 6, 2014, JAMA Otolaryngology*). And although many ... (about 50 percent according to recent polls) facing hearing loss ... a person feels and relates to the world. People who ... also made by way of:, , self-confidence ...
(Date:12/24/2014)... Today, UWDress.com, the famous women’s dress supplier, ... and launched a site-wide wedding gown promotion. , ... in a more unexpected way, the collection should be a ... the global market, and they are available with custom service. ... at discounted prices, up to 75% off; most of them ...
(Date:12/24/2014)... 2014 Mike Billings , PT, ... Derek Fenwick, PT, MBA, GCS, Director of Professional ... from the passing of the Improving Medicare Post-Acute ... this taping of the Infinicast, the two leaders discuss ... Social Security Act to standardize post-acute assessment data for ...
(Date:12/24/2014)... The holidays can be a challenge for people who suffer ... drinks. "This is the season in which many people ... David Dodick, chair of the American Migraine Foundation, said in ... think through food and beverage choices, to help reduce the ... of neurology at the Mayo Clinic in Scottsdale, Ariz. , ...
(Date:12/24/2014)... Adults who experienced childhood abuse or neglect have ... study published online Dec. 24 in the journal ... long-lasting effects, like associated medical and psychological conditions ... director of behavioral medicine at Montefiore Headache Center ... news release. "When managing patients with migraine, ...
Breaking Medicine News(10 mins):Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:Expert Offers Tips for Preventing Holiday Migraines 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2
... consumer,employer and labor organizations today announced a ... health insurers on principles,to guide how health ... to consumers., The "Patient Charter for ... today creates a national set of principles,to ...
... Turns Assets from Retirement Plans Into Guaranteed Income for ... ... NEW YORK, April 1, 2008 AXA Equitable Life,Insurance Company, ... variable annuity -- Crossings(SM): My Lifetime,IRA(SM), designed specifically as a ...
... disease , , TUESDAY, April 1 (HealthDay News) -- The weight-loss ... buildup of arterial plaque that,s connected with carrying too much ... evidence that the drug actually slowed disease progression, although it ... in arteries. , Acomplia also showed a high rate ...
... drug discovery and the pharmaceutical industry currently underway will ... to a top researcher at the National Institutes of ... drug research and development. , According to ... Center (NCGC), both industry and academia welcome more cooperation ...
... 2008) A catheter-mounted device that acts like a ... heart valve is not only reducing the abnormal backflow ... atrium, it is helping to shrink the enlarged, overworked ... surgery. These are the one-year findings in a small ...
... A new study has found that an x-ray dye ... prevent renal injury during percutaneous coronary intervention (PCI) in ... it made no difference in the need for dialysis ... the Contrast Media and Nephrotoxicity Following Coronary Revascularization by ...
Cached Medicine News:Health News:Consumers, Health Care Purchasers, Physicians, and Health Insurers Announce Agreement on Principles to Guide Physician Performance Reporting 2Health News:Consumers, Health Care Purchasers, Physicians, and Health Insurers Announce Agreement on Principles to Guide Physician Performance Reporting 3Health News:Consumers, Health Care Purchasers, Physicians, and Health Insurers Announce Agreement on Principles to Guide Physician Performance Reporting 4Health News:Consumers, Health Care Purchasers, Physicians, and Health Insurers Announce Agreement on Principles to Guide Physician Performance Reporting 5Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 2Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 3Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 4Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 5Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 6Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 7Health News:Obesity Drug Shows Mixed Success Against Atherosclerosis 2Health News:Obesity Drug Shows Mixed Success Against Atherosclerosis 3Health News:Business of drug development on verge of great change 2Health News:Catheter repair of mitral valve improves heart size, symptoms 2Health News:Catheter repair of mitral valve improves heart size, symptoms 3Health News:Iso-osmolar X-ray dye falters in PCI study 2Health News:Iso-osmolar X-ray dye falters in PCI study 3
(Date:12/24/2014)... , Dec. 24, 2014  Conkwest, Inc., the ... the proprietary Natural Killer (NK) cell-line platform, Neukoplast® ... Patrick Soon-Shiong , NantWorks founder, physician scientist ... agreement to purchase approximately $48 million of the ... the investment, he will be named Co-Chairman of ...
(Date:12/24/2014)... 2014 Echo Therapeutics, Inc. (NASDAQ: ... on skin permeation, continuous glucose monitoring and associated ... has been appointed Chief Executive Officer effective ... 20 years of experience in the medical device, ... served as Vice President, Business Development, Otsuka Pharmaceuticals as ...
(Date:12/24/2014)... Dec. 23, 2014   Assurex Health, a ... to healthcare providers for behavioral health and chronic ... $30 million in equity financing from new and ... , President and Chief Executive Officer. ... development of Assurex Health,s GeneSight ® ...
Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... in Patients Reduces,Severity of Adult Leukaemia , Copenhagen, ... company, announced today that SPC2996, the,Company's new RNA ... in an initial Phase I/II clinical study in ... were reported,this week at the 2007 Annual Meeting ...
... Shows Safety and Pharmacokinetics Similar to IV ... N.J., June 06, 2007 /PRNewswire-FirstCall/ --,Genta Incorporated ... show the Company's lead anti-cancer drug,Genasense(R) (oblimersen ... subcutaneous (SC) injection, as well,as by brief ...
Cached Medicine Technology:Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia 2Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia 3Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia 4Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia 5Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia 6Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia 7Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia 8Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia 9Genta Announces Results of Phase 1 Study Using Genasense,Administered by Intermittent Subcutaneous Injection 2Genta Announces Results of Phase 1 Study Using Genasense,Administered by Intermittent Subcutaneous Injection 3Genta Announces Results of Phase 1 Study Using Genasense,Administered by Intermittent Subcutaneous Injection 4
Batch Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 40 tests....
For use with catalog #0540....
Enzyme Immunoassay of D-Dimer by ELISA Method, 96 tests....
Lupus Anticoagulant-Sensitive APTT Reagent.Cephalin with particulate activator (silica), freeze-dried....
Medicine Products: